来自肠道微生物的芳香微氨酸调解了对功能性便秘的草药CDD-2101的反应中的个体变异性
Shifa Ruan1, Yaqi Li1, Ziwan Ning1
1Centre for Chinese Medicine Drug Development Limited, Hong Kong Baptist University, Hong Kong, China.
Pharmacological research
|June 1, 2025
概括
一种植物药物CDD-2101通过增加产生芳香微量胺的肠道细菌来改善功能性便秘. 这种机制增强了血清素的产生和肠道功能,提供了一个新的治疗点.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 功能性便秘 (FC) 存在治疗挑战,原因是当前疗法的有效性有限.
- 准肠道失生症是FC的新策略.
- 植物药物CDD-2101在CF患者中表现有前途,但其机制尚不清楚.
研究的目的:
- 为了研究CDD-2101诱导的肠道微生物群变化在FC患者中.
- 阐明CDD-2101改善肠道功能的机制.
- 为了确定FC的微生物衍生的治疗点.
主要方法:
- 在接受CDD-2101治疗的FC患者中分析肠道微生物群组成和代谢物概况.
- 在小鼠中进行的临床前研究使用了胺和工程Lactobacillus casei.
- 对跟踪氨基相关受体1 (TAAR1) - 血清素轴的研究.
主要成果:
- 在CF患者中,CDD-2101丰富了芳香微量胺和产生细菌的细菌,与改善的肠功能和血清激素水平相关.
- 治疗患者的提拉明或便微生物种移植改善了小鼠的便秘.
- 芳香性微氨基激活TAAR1-氨酸轴,增强胃肠道的运动性.
结论:
- 由肠道细菌产生的芳香微量胺是CDD-2101在功能性便秘中的有效性的关键调解剂.
- 芳香微量胺-氨酸轴代表了FC的有前途的治疗标.
- 准肠道微生物群为管理功能性便秘提供了一个可行的策略.
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
421
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
421
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
328
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
328
01:20Drugs Affecting GI Tract Motility: Other Laxatives
486
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
486
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
307
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
307
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
207
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
207
01:17Drugs for Treatment of Diarrhea-Predominant IBS
315
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
315